Supratentorial low-grade diffuse astrocytoma: medical management

Area of Science:

• Neuro-oncology
• Neurosurgery
• Clinical Neurology

Background:

• Diffuse astrocytomas (DAs) are WHO grade II gliomas, comprising <10% of all gliomas.
• These tumors infiltrate brain tissue and have a median survival of 5-7 years.
• DAs often undergo malignant transformation to glioblastoma (GBM).

Purpose of the Study:

• To review chemotherapy as a treatment modality for diffuse astrocytomas.
• To provide guidelines for chemotherapy usage in DA management.
• To discuss symptom management, particularly epilepsy, in diffuse astrocytoma patients.

Main Methods:

• Review of available data on chemotherapy and irradiation for diffuse astrocytomas.
• Analysis of treatment outcomes and impact on disease progression.
• Discussion of medical management strategies for tumor-associated symptoms.

Main Results:

• Adjuvant therapies, including chemotherapy and irradiation, minimally impact the disease course.
• Outcomes appear similar whether patients receive adjuvant irradiation or chemotherapy.
• Chemotherapy's role may be more focused on symptom management and delaying malignant transformation.

Conclusions:

• Current adjuvant therapies offer limited impact on diffuse astrocytoma survival.
• Chemotherapy guidelines are needed for DA treatment, focusing on symptom control and preventing progression.
• Effective symptom management, especially for epilepsy, is crucial in diffuse astrocytoma care.